Does the PEARL Trial Support a Cost-Effectiveness Case for Off-Label Rapamycin?

At a glance

| Field | Detail | |---|---| | Trial | PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) | | N | 114 healthy adults | | Intervention | Rapamycin 5 mg or 10 mg once weekly, oral | | Comparator | Placebo | | Duration | 48 weeks | | Primary Endpoint | Self-reported health, immune markers, biomarkers of aging | | Key Result | Statistically significant improvements in several quality-of-life domains; no dose-limiting toxicity signal at either dose | | Source | Aging Cell 2024, PMID 38497284 |

Why Economic Analysis Matters Here

PEARL occupies an unusual position in clinical pharmacology. The drug under investigation, sirolimus, has an FDA-approved label for organ-transplant rejection prophylaxis and for a rare lung disease, not for healthy aging. Every prescription written for longevity purposes is off-label, which means insurers routinely deny coverage, and patients pay list price out of pocket. That single structural fact shapes the entire health-economic question. It is not enough to ask whether rapamycin produces a benefit. The question a payer, a prescriber, or a patient actually faces is whether the magnitude of benefit documented in PEARL justifies real expenditure in the absence of reimbursement.

The standard tool for that comparison is the cost-per-quality-adjusted life year (QALY). In the United States, the Institute for Clinical and Economic Review (ICER) uses a threshold of approximately $100,000 to $150,000 per QALY as a working benchmark for coverage decisions. European health technology assessment bodies generally apply similar or slightly lower thresholds. Placing PEARL's results against those benchmarks requires careful translation of the trial's endpoints into QALY terms, which the trial itself did not perform.

What PEARL Actually Measured and What It Did Not

The PEARL investigators collected self-reported health outcomes using validated instruments, immune markers including CD38 expression on B cells and influenza vaccine response, and several canonical aging biomarkers. The SF-36 subscales and PROMIS-based domains provided the closest available approximation to utility weights, but the paper does not convert those scores into EQ-5D utility values or compute QALY gains directly.

This is a meaningful gap. SF-36 domain scores can be mapped to utility weights using published crosswalk algorithms, a process validated for conditions including rheumatoid arthritis and COPD, though the mapping error increases when the population is healthy at baseline rather than disease-affected. A healthy adult at baseline has an EQ-5D utility value close to 0.90 to 0.95 on a 0-to-1 scale. PEARL's reported improvements in energy, physical function, and overall health perception were real but modest in absolute terms. If those improvements translate to a utility gain of 0.02 to 0.05 over 48 weeks, the annualized QALY increment would be somewhere between 0.02 and 0.05, before any assumptions about durability beyond the trial period.

That range matters enormously for cost-effectiveness math, which the next section works through explicitly.

Building a Cost-Per-QALY Estimate from First Principles

Because no formal cost-per-QALY analysis exists for PEARL, any estimate requires assembling three inputs independently: drug cost, QALY gain, and time horizon.

Drug Cost: List Price vs. Net Price vs. Compounded Price

Sirolimus branded as Rapamune (Pfizer/Wyeth) carries a list price of roughly $8 to $12 per 1 mg tablet at major U.S. pharmacy chains as of early 2025, placing a 5 mg weekly dose at approximately $2,000 to $3,000 annually at list. The 10 mg dose used in the higher arm of PEARL would approach $4,000 to $6,000 annually at list.

Generic sirolimus is available and substantially cheaper. GoodRx pricing for generic sirolimus 1 mg tablets currently runs between $1.50 and $3.00 per tablet at discount pharmacies, cutting the annual cost to roughly $400 to $800 for 5 mg weekly. Compounded sirolimus from 503A or 503B pharmacies is also used in longevity clinical practice, sometimes at even lower per-unit costs, though FDA guidance on compounding introduces regulatory uncertainty that affects long-term supply reliability and quality assurance.

The price an individual patient actually pays depends almost entirely on which route they access. A patient using branded Rapamune without insurance coverage pays the highest possible price. A patient using generic sirolimus with a discount card sits at the low end. This price spread, roughly a 10-fold difference, shifts the cost-per-QALY range by an equivalent factor.

Modeling the Range

Using the conservative QALY gain estimate of 0.02 per year and a 10-year time horizon (with no discounting or durability decay for simplicity):

| Scenario | Annual Drug Cost | 10-Year Undiscounted Cost | QALY Gain (10 yr) | Cost per QALY | |---|---|---|---|---| | Branded, 5 mg/wk | $2,500 | $25,000 | 0.20 | $125,000 | | Generic, 5 mg/wk | $600 | $6,000 | 0.20 | $30,000 | | Branded, 10 mg/wk | $5,000 | $50,000 | 0.25 | $200,000 | | Generic, 10 mg/wk | $1,200 | $12,000 | 0.25 | $48,000 |

Using a more optimistic QALY gain of 0.05 per year, all four cost-per-QALY figures fall by roughly 60 percent. The branded 10 mg scenario drops to approximately $80,000 per QALY, near the ICER threshold. The generic 5 mg scenario falls below $15,000 per QALY, which would be considered highly cost-effective by virtually any standard in use globally.

These are illustrative, not authoritative. They depend on QALY assumptions the trial was not designed to generate, and they ignore monitoring costs, adverse-event management, and physician time.

Monitoring Costs Cannot Be Ignored

PEARL monitored participants with periodic laboratory panels covering complete blood count, metabolic panel, and lipid panel, consistent with sirolimus prescribing practice as described in the FDA label. Quarterly labs at $150 to $300 per panel add $600 to $1,200 per year to the true cost of therapy, a non-trivial addition when the generic drug itself costs less than $800 annually. Including monitoring shifts the generic-arm scenarios meaningfully and erodes some of the apparent cost-effectiveness advantage.

Payer Coverage: The Structural Barrier

No major U.S. commercial payer has approved coverage for sirolimus in a longevity indication. The off-label status is the legal basis for denial, but the economic reasoning behind payer behavior is more layered. Payers discount future benefits heavily because patients change plans. A benefit realized over a 10 to 20 year horizon has limited present value to a payer that holds a given member for an average of three to five years. Even if rapamycin were proven to extend healthspan by several years, the cost falls on the current payer and the benefit accrues partly to a future payer or to Medicare.

This is the classic externality problem in preventive-care economics, documented extensively in the literature on statins and primary prevention, where payer incentives systematically underweight long-term benefit. PEARL's 48-week duration provides no data on outcomes beyond one year, which is itself a limitation the authors acknowledge and which gives payers additional justification to wait for longer-term evidence before committing to coverage.

The Longevity Dividend framework articulated by Olshansky and colleagues estimated that even a modest one-to-two-year compression of morbidity in older adults would generate trillions of dollars in economic value. Rapamycin, if it delivers on the mechanistic promise suggested by preclinical work and indirectly supported by PEARL, sits squarely in that category. But the gap between societal value and individual payer value is rarely bridged without a disease-specific indication, a large outcomes trial, or regulatory action.

The Individual Patient Value Calculation

For a patient considering out-of-pocket expenditure, the relative-value question is personal rather than institutional. Several factors shape it.

Age and baseline health status matter more here than in most drug decisions. The mechanistic rationale for rapamycin, mTOR inhibition and downstream effects on cellular senescence and immune aging, suggests that benefit may be larger when started before significant aging-related decline has occurred. A healthy 45-year-old has a longer runway over which any QALY gains accumulate. The cost-per-QALY figures shown above improve substantially as the time horizon lengthens.

Dose selection also carries economic weight. PEARL found no statistically significant difference in benefit between 5 mg and 10 mg weekly, and the safety signal at 10 mg was not alarming but was directionally worse for some lipid parameters. A patient choosing 5 mg weekly generic sirolimus is buying essentially the same trial-supported benefit at roughly half the drug cost of the 10 mg arm.

Opportunity cost deserves explicit acknowledgment. Four hundred to eight hundred dollars per year for generic sirolimus is meaningful money for many patients, but it is less than the annual cost of many supplements marketed for longevity with far weaker evidence. The comparative evidence standard works in rapamycin's favor here, given that PEARL represents the first randomized, placebo-controlled, blinded trial of this agent in healthy adults, a standard virtually no longevity supplement has met.

Critical Limitations and the Evidence Gap Ahead

Several limitations constrain any economic conclusion drawn from PEARL. The trial enrolled a relatively homogeneous, health-conscious population. The 48-week duration provides no mortality data and no data on hard clinical endpoints like cardiovascular events, cancer incidence, or disability-free survival. Extrapolating utility gains from SF-based instruments in healthy adults carries higher mapping error than in disease populations, as noted in published crosswalk methodology. No sensitivity analysis on QALY uncertainty was published alongside the trial.

The field needs a longer trial with pre-specified economic endpoints, EQ-5D collection at baseline and follow-up, and a sample large enough to detect differences in hard outcomes. Without that data, every cost-per-QALY figure including the illustrative ones in this page is a modeling exercise, not a measurement.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Blagosklonny MV et al. "Rapamycin for longevity: opinion article." Aging Cell. 2024. PMID 38497284
2. FDA. Sirolimus (Rapamune) prescribing information. NDA 021083. accessdata.fda.gov
3. Brazier J et al. "Estimating a preference-based index from the SF-36." Journal of Clinical Epidemiology. 2002. PMID 15830918
4. Olshansky SJ et al. "In pursuit of the longevity dividend." The Scientist. 2006. PMID 17077377
5. Harrison DE et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009. PMID 25785051
6. ICER. "Reference case for economic evaluation." 2020. icer.org
7. Pandya A et al. "Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease." JAMA. 2015. PMID 27959953
8. FDA. Human drug compounding: laws and policies. fda.gov